Chronic Lymphocytic Leukemia Therapeutics Market Revenue Opportunies By Top Key Players F. Hoffmann-La Roche, GlaxoSmithKline Pharmaceuticals, Teva Pharmaceutical Industries, AstraZeneca, Arno Therapeutics, Genzyme Corporation and Gilead Sciences

Coherent Market Insights has announced the addition of the “Chronic Lymphocytic Leukemia Therapeutics Market Size Status and Forecast 2026”, The report classifies the global Chronic Lymphocytic Leukemia Therapeutics Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global Chronic Lymphocytic Leukemia Therapeutics Speaker market, analyzes and researches the Chronic Lymphocytic Leukemia Therapeutics Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like F. Hoffmann-La Roche Ltd, Novartis International AG, GlaxoSmithKline Pharmaceuticals Limited, Celgene Corporation, Genmab A/S, Abbvie Inc. Teva Pharmaceutical Industries Ltd., Biogen Idec, AstraZeneca plc, Arno Therapeutics, Genzyme Corporation, Gilead Sciences INC.

Download PDF Brochure of this report: https://www.coherentmarketinsights.com/insight/request-pdf/2049

Chronic lymphocytic leukemia (CLL) is a most common type of leukemia found in adults. It is a kind of malignancy characterized by production of abnormal white blood cells in the bone marrow. Symptoms include, swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Although CLL is rarely seen in children and people under age 40, it is more prevalent in geriatric population. Moreover, causes of CLL are largely unknown and it is more severe than acute leukemia. The prevalence of CLL is high in males than females. Although, the incidence of this disorder is higher in white population than Asian populations, the precise cause for this cannot be explained.

The diagnosis of CLL includes Blood Cell Count and Examination, Bone Marrow Examination for patients followed by treatment. The treatment includes single or combination drug therapy, targeted therapies, monoclonal antibody therapies, white blood cell (neutrophil) growth factors. In addition to this, there are radiation therapy and splenectomy which are rarely used for the treatment.

Chronic Lymphocytic Leukemia Therapeutics Market - Drivers

High prevalence of CLL coupled with its high mortality rate, demonstrates the unmet market need for better therapeutics. According to the American Cancer Society (ACS) estimates, around 20,110 new cases of chronic lymphocytic leukemia and 4,660 deaths from CLL is expected in year 2017 in U.S. Furthermore, high prevalence of CLL in geriatric population is expected to increase demand for chronic lymphocytic leukemia therapeutics. According to the United Nations data, in 2015, around 901 million people in the world were over 60 years of age and this number is expected to reach 1.4 billion by 2030 and to 2.1 billion by 2050.

However, continuous research and development may contribute to the development of new treatments related to malignancies, including impaired immune system, genetic factors, and viruses. Thus expected to boost the market growth during the forecast period.

Furthermore, increasing number of incidences of comorbidities, especially among geriatric population and launch of new pipeline drugs are major factors contributing to growth of the chronic lymphocytic leukemia therapeutics market. For instance, on December 8, 2015, Bendeka injection—manufactured under the collaboration of Teva Pharmaceuticals Industries Ltd. and Eagle Pharmaceuticals Inc. acquired approval from FDA for the treatment of patients with CLL and indolent B-cell non-Hodgkin lymphoma (NHL) — progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Chronic Lymphocytic Leukemia Therapeutics Market Taxonomy

By Drug

Bendamustine Hydrochloride (Treanda)
Prednisone
Idelalisib (Zydelig)
Venetoclax (Venclexta)
Ibrutinib (Imbruvica)
Ofatumumab (Arzerra)
Fludarabine (Fludara)
Obinutuzumab (Gazyva)
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

North America accounted for the largest market share in 2016 due to the presence of breakthrough pipeline drugs. For instance, the drug Acalabrutinib—manufactured by Acerta Pharma BV—is under phase 2 clinical trial for the treatment of CLL and small lymphocytic lymphoma (SLL) and the study is expected to complete in January 2019. Increasing research activities along with increasing prevelance of CLL in US expected to propel the growth of CLL in North America. According to the Leukemia & Lymphoma Society, US, there are 119,386 patients in 2013 which has been increased to 15,720 in 2014.

What Information does this report contain?

-Historical data coverage: 2013 to 2017; Growth Projections: 2018 to 2026.
-Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
-6-7 year performance forecasts: major segments covering applications, top products and geographies.
-Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Else place an Inquire before Purchase “Chronic Lymphocytic Leukemia Therapeutics Market Size, Status and Forecast 2026: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2049

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.